share_log

SEI Inv Analyst Ratings

Benzinga ·  Oct 26, 2023 08:31
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/26/2023 12.13% Morgan Stanley $63 → $61 Maintains Underweight
10/05/2023 25% Oppenheimer $71 → $68 Maintains Outperform
10/03/2023 17.65% Piper Sandler $65 → $64 Maintains Neutral
10/03/2023 15.81% Morgan Stanley $65 → $63 Maintains Underweight
07/27/2023 25% Keefe, Bruyette & Woods $66 → $68 Maintains Market Perform
07/27/2023 19.49% Morgan Stanley $62 → $65 Maintains Underweight
07/05/2023 30.51% Oppenheimer $68 → $71 Maintains Outperform
07/05/2023 13.97% Morgan Stanley $60 → $62 Maintains Underweight
06/01/2023 10.29% Morgan Stanley $58 → $60 Maintains Underweight
04/04/2023 25% Oppenheimer → $68 Reiterates → Outperform
04/03/2023 6.62% Morgan Stanley $54 → $58 Maintains Underweight
03/29/2023 10.29% Piper Sandler → $60 Initiates Coverage On → Neutral
02/01/2023 -0.74% Morgan Stanley $53 → $54 Maintains Underweight
01/26/2023 25% Oppenheimer $65 → $68 Maintains Outperform
12/01/2022 -2.57% Morgan Stanley $51 → $53 Maintains Underweight
11/23/2022 15.81% Goldman Sachs $56 → $63 Maintains Neutral
11/16/2022 23.16% Oppenheimer $59 → $67 Maintains Outperform
10/04/2022 -6.25% Morgan Stanley $52 → $51 Maintains Underweight
07/21/2022 -4.41% Morgan Stanley $55 → $52 Maintains Underweight
07/15/2022 1.1% Keefe, Bruyette & Woods $62 → $55 Maintains Market Perform
07/12/2022 Morgan Stanley Downgrades Equal-Weight → Underweight
07/06/2022 1.1% Morgan Stanley $58 → $55 Maintains Equal-Weight
06/02/2022 6.62% Morgan Stanley $62 → $58 Maintains Equal-Weight
04/21/2022 13.97% Morgan Stanley $68 → $62 Maintains Equal-Weight
03/28/2022 19.49% Goldman Sachs $67 → $65 Downgrades Buy → Neutral
03/28/2022 25% Morgan Stanley $75 → $68 Maintains Equal-Weight
01/27/2022 28.68% Oppenheimer $75 → $70 Maintains Outperform
11/03/2021 23.16% Truist Securities → $67 Initiates Coverage On → Hold
11/02/2021 23.16% Truist Securities → $67 Initiates Coverage On → Hold
07/22/2021 37.87% Oppenheimer $72 → $75 Maintains Outperform
04/22/2021 36.03% Morgan Stanley $75 → $74 Maintains Equal-Weight
04/01/2021 37.87% Morgan Stanley $74 → $75 Maintains Equal-Weight
01/28/2021 36.03% Morgan Stanley $72 → $74 Maintains Equal-Weight
01/06/2021 29.6% Goldman Sachs → $70.5 Initiates Coverage On → Buy
11/30/2020 32.35% Morgan Stanley → $72 Downgrades Overweight → Equal-Weight
10/06/2020 15.81% Morgan Stanley → $63 Initiates Coverage On → Overweight
04/24/2020 6.62% Oppenheimer $60 → $58 Maintains Outperform
04/15/2019 Keefe, Bruyette & Woods Downgrades Outperform → Market Perform

What is the target price for SEI Inv (SEIC)?

The latest price target for SEI Inv (NASDAQ: SEIC) was reported by Morgan Stanley on October 26, 2023. The analyst firm set a price target for $61.00 expecting SEIC to rise to within 12 months (a possible 12.13% upside). 17 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for SEI Inv (SEIC)?

The latest analyst rating for SEI Inv (NASDAQ: SEIC) was provided by Morgan Stanley, and SEI Inv maintained their underweight rating.

When is the next analyst rating going to be posted or updated for SEI Inv (SEIC)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SEI Inv, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SEI Inv was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.

Is the Analyst Rating SEI Inv (SEIC) correct?

While ratings are subjective and will change, the latest SEI Inv (SEIC) rating was a maintained with a price target of $63.00 to $61.00. The current price SEI Inv (SEIC) is trading at is $54.40, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment